In this issue:
An Italian programme for COVID-19 infection in MS
Risk of macrovascular events and mortality with MS
Efficacy of three neuroprotective drugs in SPMS
pNfL levels are associated with risk of disability in MS
EBV seropositivity in a large cohort of patients with early MS
A longitudinal study of cognitive function in MS
Classification of fatigue in MS based on longitudinal assessments
COVID-19 in persons with MS treated with ocrelizumab
Distinguishing neurosarcoidosis from MS based on CSF analysis
Influence of age at disease onset on future relapses and disability progression in patients with MS on DMTs
Please login below to download this issue (PDF)